Pfizer Inc (PFE): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Pfizer ( PFE) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.7%. By the end of trading, Pfizer rose 42 cents (1.7%) to $24.67 on average volume. Throughout the day, 29 million shares of Pfizer exchanged hands as compared to its average daily volume of 28.8 million shares. The stock ranged in a price between $24.15-$24.69 after having opened the day at $24.23 as compared to the previous trading day's close of $24.25. Other companies within the Drugs industry that increased today were: Vermillion ( VRML), up 39.5%, TrovaGene ( TROV), up 20.2%, PharmAthene ( PIP), up 17.9%, and Idenix Pharmaceuticals ( IDIX), up 17.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. Pfizer has a market cap of $180.27 billion and is part of the health care sector. The company has a P/E ratio of 19, above the S&P 500 P/E ratio of 17.7. Shares are up 13.1% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate Pfizer a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Telik ( TELK), down 14.8%, Idera Pharmaceuticals ( IDRA), down 12.5%, Oxygen Biotherapeutics ( OXBT), down 10.3%, and Zalicus ( ZLCS), down 8.9%, were all laggards within the drugs industry with Vertex Pharmaceuticals ( VRTX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign